Statin use and the risk of esophageal cancer: a population-based case-control study

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Expert Opinion on Drug Safety

• Publication date

  2013-04-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14740338.2013.778241PMID 23470154
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Use of Statin Medications and Risk of Esophageal Adenocarcinoma in Persons with Barrett's Esophagus

  2012cited by this paper
• Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus.

  2011cited by this paper
• Exposure to statins and risk of common cancers: a series of nested case-control studies

  2011cited by this paper
• Analgesic use and the risk for progression of chronic kidney disease

  2010cited by this paper
• Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus.

  2010cited by this paper
• The double-edged sword of statin immunomodulation.

  2009cited by this paper
• Medication usage and the risk of neoplasia in patients with Barrett's esophagus.

  2009cited by this paper
• Statins inhibit NK‐cell cytotoxicity by interfering with LFA‐1‐mediated conjugate formation

  2009cited by this paper
• The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells.

  2008cited by this paper
• Screening statins for possible carcinogenic risk: up to 9 years of follow‐up of 361 859 recipients

  2008cited by this paper
• Statins Inhibit Proliferation and Induce Apoptosis in Barrett's Esophageal Adenocarcinoma Cells

  2008cited by this paper
• Do statins prevent or promote cancer?

  2008cited by this paper
• Statins in Esophageal Cancer Cell Lines: Promising Lead?

  2008cited by this paper
• Inhibition of Barret's adenocarcinoma cell growth by simvastatin: involvement of COX-2 and apoptosis-related proteins.

  2007cited by this paper
• Statin Use and the Risk of 10 Cancers

  2007cited by this paper
• Trends in the use of antihypertensive drugs by outpatients with diabetes in Taiwan, 1997–2003

  2007cited by this paper
• Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

  2007cited by this paper
• Epidemiological features of CKD in Taiwan.

  2007cited by this paper
• Statins and osteoporosis: new role for old drugs

  2006cited by this paper
• Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.

  2005cited by this paper
• Cancer risk among statin users: A population‐based cohort study

  2005cited by this paper
• Hip fracture risk in statin users—a population-based Danish case-control study

  2004cited by this paper
• Statin use and cancer risk in the General Practice Research Database

  2004cited by this paper
• Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial

  2003cited by this paper
• Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models.

  2003cited by this paper
• 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation.

  2002cited by this paper
• Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.

  2002cited by this paper
• 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Interfere With Angiogenesis by Inhibiting the Geranylgeranylation of RhoA

  2002cited by this paper
• 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: Implications for diabetic nephropathy

  2002cited by this paper
• Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas.

  2002cited by this paper
• Statins Have Biphasic Effects on Angiogenesis

  2002cited by this paper
• HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis

  2002cited by this paper
• Statin Use and the Risk of Breast and Prostate Cancer

  2002cited by this paper
• Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors.

  2001cited by this paper
• HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients.

  2000cited by this paper
• HMG-CoA reductase inhibitors and the risk of fractures.

  2000cited by this paper
• Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase.

  1999cited by this paper
• Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials.

  1997cited by this paper
• Carcinogenicity of lipid-lowering drugs.

  1996cited by this paper
• Carcinogenicity of lipid-lowering drugs.

  1996cited by this paper
• Effect of pravastatin on outcomes after cardiac transplantation.

  1995cited by this paper
• Nested case-control studies.

  1994cited by this paper
• Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin.

  1991cited by this paper

• Assessing the role of lipid-lowering therapy on multi-cancer prevention: A mendelian randomization study

  2023cites this paper
• Statins and the risk of gastric, colorectal, and esophageal cancer incidence and mortality: a cohort study based on data from the Korean national health insurance claims database

  2022cites this paper
• Statins as Potential Therapeutics for Esophageal Cancer

  2021cites this paper
• andMeta-analysis : Use of Statins Is Associated with a Reduced Incidence of Oesophageal Adenocarcinoma

  2017cites this paper
• Adverse effects of statins - myths and reality.

  2015cites this paper
• Statins are potential anticancerous agents (review).

  2015cites this paper
• Statins in the primary prevention of cardiovascular disease

  2013cites this paper